You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PIK3CA H1047R mutation

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Patterns Among PIK3CA Mutation in Advanced Breast Cancer

Completed
  • Breast Cancer
    • East Hanover, New Jersey
      Novartis
    Aug 1, 2023

    Lymphatic Malformations Trial (Alpelisib, Placebo)

    Not yet recruiting
    • Lymphatic Malformations
    • (no location specified)
    Jul 4, 2023

    PIK3CA Mutation-Related Tumors Trial in Shanghai (WX390)

    Completed
    • PIK3CA Mutation-Related Tumors
    • Shanghai, Shanghai, China
      Shanghai East Hospital
    Nov 9, 2023

    Advanced Breast Cancer Trial in Thalassery (Alpelisib, Fulvestrant)

    Recruiting
    • Advanced Breast Cancer
    • Thalassery, Kerala, India
      Novartis Investigative Site
    Nov 21, 2022

    A NIS of Alpelisib in Combination With Fulvestrant in

    Not yet recruiting
    • Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation
    • Alpelisib
    • Fulvestrant
    • (no location specified)
    Aug 9, 2022

    Advanced Breast Cancer Trial in Orebro (Alpelisib, fulvestrant)

    Terminated
    • Advanced Breast Cancer
    • Orebro, Sweden
    • +1 more
    Nov 21, 2022

    Endometrial Cancer, Ovarian Cancer Trial in Houston (Copanlisib, fulvestrant)

    Recruiting
    • Endometrial Cancer
    • Ovarian Cancer
    • Houston, Texas
      M D Anderson Cancer Center
    Sep 27, 2022

    PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer Trial (RLY-5836, Fulvestrant, Palbociclib)

    Not yet recruiting
    • PIK3CA Mutation
    • +7 more
    • (no location specified)
    Mar 7, 2023

    Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Taselisib)

    Active, not recruiting
    • Advanced Lymphoma
    • +5 more
    • Philadelphia, Pennsylvania
      ECOG-ACRIN Cancer Research Group
    Feb 4, 2022

    Patogenic Mutation in 5 Genes

    Completed
    • Colorectal Cancer
    • +5 more
    • co-occuring mutation
    • Jakarta, ALL, Indonesia
      Vania Myralda Giamour Marbun
    Jul 21, 2021

    Advanced Solid Tumor, PIK3CA Mutation, PTEN Loss of Function Mutation Trial in United States (Serabelisib, Insulin Suppressing

    Recruiting
    • Advanced Solid Tumor
    • +2 more
    • Birmingham, Alabama
    • +9 more
    May 25, 2022

    Solid Tumors, Adult, PIK3CA Mutation-Related Tumors, PIK3CA Mutation Trial in San Francisco (Alpelisib, Carboplatin,

    Not yet recruiting
    • Solid Tumors, Adult
    • +7 more
    • San Francisco, California
      University of California, San Francisco
    Jul 21, 2022

    HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer Trial (Evexomostat)

    Not yet recruiting
    • HR+/HER2-negative Breast Cancer
    • Metastatic Breast Cancer
    • (no location specified)
    Jul 7, 2022

    Slow-Flow Vascular Malformation, Fast-Flow Vascular Malformation, Vascular Malformations Trial in Parkville (Alpelisib,

    Not yet recruiting
    • Slow-Flow Vascular Malformation
    • +17 more
    • Parkville, Victoria, Australia
      The Royal Children's Hospital
    Aug 7, 2023

    Breast Cancer Trial in Shanghai (HS-10352 combined with fulvestrant (Stage 1), HS-10352 combined with fulvestrant (Stage 2))

    Recruiting
    • Breast Cancer
    • HS-10352 combined with fulvestrant (Stage 1)
    • HS-10352 combined with fulvestrant (Stage 2)
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Aug 15, 2022

    PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome Trial in Worldwide (Miransertib)

    Terminated
    • PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome
    • Atlanta, Georgia
    • +10 more
    May 10, 2022

    PIK3CA-related Overgrowth Spectrum (PROS) Trial in Worldwide (Alpelisib, Placebo)

    Recruiting
    • PIK3CA-related Overgrowth Spectrum (PROS)
    • Los Angeles, California
    • +38 more
    Nov 25, 2022

    Breast Cancer Trial in Spain (Alpelisib, Metformin, Fulvestrant)

    Active, not recruiting
    • Breast Cancer
    • Alicante, Spain
    • +17 more
    Aug 23, 2022

    Advanced Endometrial Cancer, Cervical Cancer and Ovarian Cancer Trial in China (TQ-B3525 tablet)

    Recruiting
    • Advanced Endometrial Cancer, Cervical Cancer and Ovarian Cancer
    • TQ-B3525 tablet
    • Changzhou, Jiangsu, China
    • +4 more
    May 27, 2021

    Metastatic Colorectal Cancer, PIK3CA Gene Mutation Trial (Alpelisib plus Capecitabine combination)

    Not yet recruiting
    • Metastatic Colorectal Cancer
    • PIK3CA Gene Mutation
    • Alpelisib plus Capecitabine combination
    • (no location specified)
    Feb 11, 2021

    Advanced or Metastatic Breast Cancer, ER+ve Advanced or Metastatic Breast Cancer Trial in Worldwide (AZD5363 when combined with

    Completed
    Has Results
    • Advanced or Metastatic Breast Cancer
    • ER+ve Advanced or Metastatic Breast Cancer
    • AZD5363 when combined with weekly paclitaxel.
    • +2 more
    • Plovdiv, Bulgaria
    • +40 more
    Dec 23, 2022

    Triple Negative Breast Tumors Trial in Worldwide (alpelisib, , nab-paclitaxel)

    Active, not recruiting
    • Triple Negative Breast Neoplasms
    • Los Alamitos, California
    • +154 more
    Jan 12, 2023

    Solid Tumor, Colorectal Cancer, Non Small Cell Lung Cancer Trial in United States (TPST-1495 twice daily, TPST-1495 once daily

    Recruiting
    • Solid Tumor
    • +8 more
    • TPST-1495 twice daily
    • +2 more
    • Baltimore, Maryland
    • +8 more
    Jan 4, 2023

    Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Metastatic Breast Carcinoma Trial in United States

    Recruiting
    • Anatomic Stage IV Breast Cancer AJCC v8
    • +2 more
    • Los Angeles, California
    • +4 more
    Jul 19, 2022

    Tolerability Outcomes of Alpelisib in Real-world

    Recruiting
    • Breast Cancer
    • alpelisib plus fulvestrant
    • Mumbai, Maharashtra, India
    • +3 more
    Jun 8, 2022